Our Take
Haleon is committing long-term capital to India's consumer health market, but the 2029–30 timeline means supply benefits and job creation are years away.
Why it matters
India's consumer health sector is growing faster than most Western markets, and Haleon (a £14 billion revenue company spun from GSK and Pfizer in 2022) is signaling that local manufacturing, not just imports, is essential to compete here. The facility also signals confidence in Indian industrial policy and labor availability.
Do this week
Supply chain heads: monitor this project's progress at Pithampur; if it opens on schedule, expect Haleon to compete harder on delivery times and pricing in India and Southeast Asia starting 2030.
Haleon commits ₹2,000 crore to Indian greenfield manufacturing
Haleon, the consumer health company spun off from GSK and Pfizer in 2022, announced a ₹2,000 crore (£175 million) investment to build its first manufacturing facility in India. The facility will be located on a 40-acre site in Pithampur, Madhya Pradesh, and is scheduled to become operational by 2029–30 (per company announcement via ET HealthWorld).
The plant will feature automated manufacturing capabilities and is projected to create up to 500 direct jobs, plus indirect employment in the region. The company cited rising demand for its products, including the Sensodyne toothpaste brand, as a driver for the investment.
Brian McNamara, CEO of Haleon, stated the investment "strengthens our local manufacturing footprint and expands our reach in one of the world's fastest-growing consumer health markets." Haleon currently operates in more than 170 markets and reported $14 billion in revenue in 2025 (company-reported).
Local manufacturing shifts supply risk in India
Until now, Haleon has served India primarily through imports. A domestic facility eliminates tariffs on inbound goods and reduces logistics complexity for a market where consumer health products face intense price competition. The move also signals Haleon's confidence in India's manufacturing infrastructure and policy environment at a time when other multinationals are diversifying supply chains away from China.
The 2029–30 timeline is the real constraint. Three to four years of lead time means competitors already operating domestic plants will maintain a cost and delivery advantage in the interim. For Haleon, the bet is that India's market growth over the next decade justifies the upfront cost now.
What supply chain and operations leaders should track
If this facility reaches operational status on schedule, Haleon will have local capacity to serve India and potentially supply other Asian markets. For procurement teams buying from Haleon, monitor the project milestones. If the facility launches as planned, expect the company to adjust pricing and delivery terms for Indian and regional customers, likely pressuring margins in the market.
For facility operators and industrial policy watchers, Pithampur (already home to automotive and pharmaceutical manufacturing) is becoming a hub for consumer goods automation. This investment is one of several by global brands moving into the region.